An Early Access Program for Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Trial Profile

An Early Access Program for Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 08 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top